Medication-Assisted Treatment for Opioid-Use Disorder

Brook, 2017, The chemical history of morphine: an 8000-year journey, from resin to de-novo synthesis, J Anesth Hist, 3, 50 Sabatowski, 2004, Pain treatment: a historical overview, Curr Pharm Des, 10, 701, 10.2174/1381612043452974 Rummans, 2018, How good intentions contributed to bad outcomes: the opioid crisis, Mayo Clin Proc, 93, 344, 10.1016/j.mayocp.2017.12.020 Baker, 2017, History of the Joint Commission's pain standards: lessons for today's prescription opioid epidemic, JAMA, 317, 1117, 10.1001/jama.2017.0935 Max, 1990, Improving outcomes of analgesic treatment: is education enough?, Ann Intern Med, 113, 885, 10.7326/0003-4819-113-11-885 Puntillo, 2003, Accuracy of emergency nurses in assessment of patients' pain, Pain Manag Nurs, 4, 171, 10.1016/S1524-9042(03)00033-X Kolodny, 2015, The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction, Annu Rev Public Health, 36, 559, 10.1146/annurev-publhealth-031914-122957 1987 2011, Vital signs: overdoses of prescription opioid pain relievers–United States, 1999–2008, MMWR Morb Mortal Wkly Rep, 60, 1487 Srivastava, 2018, Beyond supply: how we must tackle the opioid epidemic, Mayo Clin Proc, 93, 269, 10.1016/j.mayocp.2018.01.018 Seth, 2018, Overdose deaths involving opioids, cocaine, and psychostimulants–United States, 2015–2016, Am J Transplant, 18, 1556, 10.1111/ajt.14905 2018 2017 Morgan, 2006, Medical and nonmedical use of prescription opioids: epidemiology and prevalence, Psychiatr Ann, 36, 10.3928/00485713-20060601-02 Vowles, 2015, Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis, Pain, 156, 569, 10.1097/01.j.pain.0000460357.01998.f1 Muhuri, 2013, 1 2013 Jones, 2013, Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers–United States, 2002-2004 and 2008-2010, Drug Alcohol Depend, 132, 95, 10.1016/j.drugalcdep.2013.01.007 Webster, 2005, Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool, Pain Med, 6, 432, 10.1111/j.1526-4637.2005.00072.x Butler, 2010, Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy, Clin J Pain, 26, 770, 10.1097/AJP.0b013e3181f195ba Babor, 2007, Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a public health approach to the management of substance abuse, Subst Abuse, 28, 7, 10.1300/J465v28n03_03 Babor, 2017, Screening, Brief Intervention and Referral to Treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice, Addiction, 112, 110, 10.1111/add.13675 Volkow, 2014, Medication-assisted therapies: tackling the opioid-overdose epidemic, N Engl J Med, 370, 2063, 10.1056/NEJMp1402780 Morgan, 2018, Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population, J Subst Abuse Treat, 85, 90, 10.1016/j.jsat.2017.07.001 Gold, 1993, Opiate addiction and the locus coeruleus: the clinical utility of clonidine, naltrexone, methadone, and buprenorphine, Psychiatr Clin North Am, 16, 61, 10.1016/S0193-953X(18)30190-4 Blumberg, 1973, Naloxone, naltrexone, and related noroxymorphones, Adv Biochem Psychopharmacol, 8, 33 Willette, 1976, The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics and sustained-release preparations, Natl Inst Drug Abuse Res, 147 Ginzburg, 1984, The role of the National Institute on Drug Abuse in the development of naltrexone, J Clin Psychiatry, 45, 4 Croop, 1997, The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. The Naltrexone Usage Study Group, Arch Gen Psychiatry, 54, 1130, 10.1001/archpsyc.1997.01830240090013 Gold, 1982, Naltrexone, opiate addiction, and endorphins, Med Res Rev, 2, 211, 10.1002/med.2610020302 Minozzi, 2011, Oral naltrexone maintenance treatment for opioid dependence, Cochrane Database Syst Rev, Cd001333 Verebey, 1981, The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics, NIDA Res Monogr, 28, 147 Sullivan, 2013, Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?, Drug Alcohol Depend, 133, 80, 10.1016/j.drugalcdep.2013.05.030 Molero, 2018, Medications for alcohol and opioid use disorders and risk of suicidal behavior, accidental overdoses, and crime, Am J Psychiatry, 175, 970, 10.1176/appi.ajp.2018.17101112 Johansson, 2006, Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review, Addiction, 101, 491, 10.1111/j.1360-0443.2006.01369.x Gold, 1984, The sequential use of clonidine and naltrexone in the treatment of opiate addicts, Adv Alcohol Subst Abuse, 3, 19, 10.1300/J251v03n03_03 Washton, 1984, Naltrexone in addicted physicians and business executives, NIDA Res Monogr, 55, 185 Washton, 1984, Successful use of naltrexone in addicted physicians and business executives, Adv Alcohol Subst Abuse, 4, 89, 10.1300/J251v04n02_08 Ling, 1984, Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience, J Clin Psychiatry, 45, 46 Brahen, 1984, Naltrexone treatment in a jail work-release program, J Clin Psychiatry, 45, 49 Navaratnam, 1994, Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts, Drug Alcohol Depend, 34, 231, 10.1016/0376-8716(94)90161-9 Marrazzi, 1997, High-dose naltrexone and liver function safety, Am J Addict, 6, 21, 10.1111/j.1521-0391.1997.tb00388.x Yen, 2006, Study of hepatotoxicity of naltrexone in the treatment of alcoholism, Alcohol, 38, 117, 10.1016/j.alcohol.2006.05.003 Ayanga, 2016, Update on pharmacotherapy for treatment of opioid use disorder, Expert Opin Pharmacother, 17, 2307, 10.1080/14656566.2016.1244529 Adi, 2007, Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation, Health Technol Assess, 11, 10.3310/hta11060 Roozen, 2006, A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence, Eur Neuropsychopharmacol, 16, 311, 10.1016/j.euroneuro.2005.11.001 Sullivan, 2007, Management of relapse in naltrexone maintenance for heroin dependence, Drug Alcohol Depend, 91, 289, 10.1016/j.drugalcdep.2007.06.013 Ahmadi, 2003, Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study, Eur J Clin Invest, 33, 824, 10.1046/j.1365-2362.2003.01218.x Rothenberg, 2002, Behavioral naltrexone therapy: an integrated treatment for opiate dependence, J Subst Abuse Treat, 23, 351, 10.1016/S0740-5472(02)00301-X Kleber, 1985, Naltrexone, J Subst Abuse Treat, 2, 117, 10.1016/0740-5472(85)90036-4 Krupitsky, 2011, Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial, Lancet, 377, 1506, 10.1016/S0140-6736(11)60358-9 Comer, 2002, Depot naltrexone: long-lasting antagonism of the effects of heroin in humans, Psychopharmacology (Berl), 159, 351, 10.1007/s002130100909 Sullivan, 2019, A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder, Am J Psychiatry, 176, 129, 10.1176/appi.ajp.2018.17070732 Brewer, 2019, Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve, Addiction, 114, 188, 10.1111/add.14448 Garbutt, 2005, Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence, JAMA, 293, 1617, 10.1001/jama.293.13.1617 Lee, 2018, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial, Lancet, 391, 309, 10.1016/S0140-6736(17)32812-X Jarvis, 2018, Extended-release injectable naltrexone for opioid use disorder: a systematic review, Addiction, 113, 1188, 10.1111/add.14180 Mannelli, 2014, Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial, Drug Alcohol Depend, 138, 83, 10.1016/j.drugalcdep.2014.02.002 Tanum, 2017, Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial, JAMA Psychiatry, 74, 1197, 10.1001/jamapsychiatry.2017.3206 Baser, 2011, Cost and utilization outcomes of opioid-dependence treatments, Am J Manag Care, 17, S235 Colquhoun, 2005, A comparison of oral and implant naltrexone outcomes at 12 months, J Opioid Manag, 1, 249, 10.5055/jom.2005.0054 Larney, 2014, A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence, Drug Alcohol Rev, 33, 115, 10.1111/dar.12095 Foster, 2003, Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels, Addict Biol, 8, 211, 10.1080/1355621031000117446 Walsh, 2003, The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic, Drug Alcohol Depend, 70, S13, 10.1016/S0376-8716(03)00056-5 Lewis, 1985, Buprenorphine, Drug Alcohol Depend, 14, 363, 10.1016/0376-8716(85)90067-5 Campbell, 2012, The history of the development of buprenorphine as an addiction therapeutic, Ann NY Acad Sci, 1248, 124, 10.1111/j.1749-6632.2011.06352.x Weinstein, 2018, Tapering off and returning to buprenorphine maintenance in a primary care office based addiction treatment (OBAT) program, Drug Alcohol Depend, 189, 166, 10.1016/j.drugalcdep.2018.05.010 Strain, 2002, Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine, Psychopharmacology, 159, 161, 10.1007/s002130100920 Li, 2014, Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies, Expert Opin Pharmacother, 15, 2263, 10.1517/14656566.2014.955469 Kampman, 2015, American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use, J Addict Med, 9, 358 Nielsen, 2016, Opioid agonist treatment for pharmaceutical opioid dependent people, Cochrane Database Syst Rev, Cd011117 Blum, 2018, A systematic, intensive statistical investigation of data from the Comprehensive Analysis of Reported Drugs (CARD) for compliance and illicit opioid abstinence in substance addiction treatment with buprenorphine/naloxone, Subst Use Misuse, 53, 220, 10.1080/10826084.2017.1400064 Lee, 2009, Home buprenorphine/naloxone induction in primary care, J Gen Intern Med, 24, 226, 10.1007/s11606-008-0866-8 Cunningham, 2011, A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions, J Subst Abuse Treat, 40, 349, 10.1016/j.jsat.2010.12.002 Fiellin, 2014, Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial, JAMA Intern Med, 174, 1947, 10.1001/jamainternmed.2014.5302 Yokell, 2011, Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review, Curr Drug Abuse Rev, 4, 28, 10.2174/1874473711104010028 Bazazi, 2011, Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users, J Addict Med, 5, 175 Cicero, 2018, Understanding the use of diverted buprenorphine, Drug Alcohol Depend, 193, 117, 10.1016/j.drugalcdep.2018.09.007 Aalto, 2007, Buprenorphine misuse in Finland, Subst Use Misuse, 42, 1027, 10.1080/10826080701434857 Schuman-Olivier, 2013, Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes, Drug Alcohol Depend, 132, 580, 10.1016/j.drugalcdep.2013.04.006 Reynaud, 1998, Six deaths linked to misuse of buprenorphine-benzodiazepine combinations, Am J Psychiatry, 155, 448, 10.1176/ajp.155.3.447-b 2004 McNicholas, 2004 Rosenthal, 2017, Advances in the delivery of buprenorphine for opioid dependence, Drug Des Devel Ther, 11, 2493, 10.2147/DDDT.S72543 Dole, 1967, Selected bibliography on narcotic addiction treatment, 1960-1966: reports of treatment programs, Am J Public Health Nations Health, 57, 2005, 10.2105/AJPH.57.11.2005 Dole, 1965, A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride, JAMA, 193, 646, 10.1001/jama.1965.03090080008002 Dole, 1968, The use of methadone for narcotic blockade, Br J Addict Alcohol Other Drugs, 63, 55, 10.1111/j.1360-0443.1968.tb05251.x Eddy, 1973 Stotts, 2009, Opioid dependence treatment: options in pharmacotherapy, Expert Opin Pharmacother, 10, 1727, 10.1517/14656560903037168 Farrell, 1994, Methadone maintenance treatment in opiate dependence: a review, BMJ, 309, 997, 10.1136/bmj.309.6960.997 Ball, 2012 Mattick, 2009, Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence, Cochrane Database Syst Rev, Cd002209 Hser, 2016, Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial, Addiction, 111, 695, 10.1111/add.13238 Zhu, 2018, Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine/naloxone in a multi-site trial, J Neuroimmune Pharmacol, 13, 488, 10.1007/s11481-018-9801-x Johansson, 2007, Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study, Nord J Psychiatry, 61, 288, 10.1080/08039480701415251 Joseph, 2000, Methadone maintenance treatment (MMT): a review of historical and clinical issues, Mt Sinai J Med, 67, 347 Lev, 2015, Methadone related deaths compared to all prescription related deaths, Forensic Sci Int, 257, 347, 10.1016/j.forsciint.2015.09.021 Gardner, 1970, Methadone misuse and death by overdosage, Br J Addict Alcohol Other Drugs, 65, 113, 10.1111/j.1360-0443.1970.tb01141.x Dasgupta, 2013, Crowdsourcing black market prices for prescription opioids, J Med Internet Res, 15, e178, 10.2196/jmir.2810 Madden, 2011, The methadone epidemic: methadone-related deaths on the rise in Vermont, Am J Forensic Med Pathol, 32, 131, 10.1097/PAF.0b013e3181e8af3d Kristensen, 1995, The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine, Life Sci, 56, PL45, 10.1016/0024-3205(94)00937-6 Eap, 2002, Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence, Clin Pharmacokinet, 41, 1153, 10.2165/00003088-200241140-00003 Haroutiunian, 2012, Methadone for chronic non-cancer pain in adults, Cochrane Database Syst Rev, 11, Cd008025 Clark, 2002, LAAM maintenance vs methadone maintenance for heroin dependence, Cochrane Database Syst Rev, Cd002210 Anglin, 2007, Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status, Addiction, 102, 1432, 10.1111/j.1360-0443.2007.01935.x Wieneke, 2009, Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation: results from a controlled clinical trial, Eur J Med Res, 14, 7, 10.1186/2047-783X-14-1-7 Weimer, 2011, The source of methadone in overdose deaths in Western Virginia in 2004, J Addict Med, 5, 188 2018 Saxon, 2018, Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry, Addiction, 113, 1477, 10.1111/add.14199 Krupitsky, 2013, Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness, Addiction, 108, 1628, 10.1111/add.12208 Chang, 2018, Adherence to extended release naltrexone: patient and treatment characteristics, Am J Addict, 27, 524, 10.1111/ajad.12786 Earley, 2017, Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence, J Addict Med, 11, 224 DuPont, 2009, Setting the standard for recovery: Physicians' Health Programs, J Subst Abuse Treat, 36, 159, 10.1016/j.jsat.2008.01.004 Mattick, 2014, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Database Syst Rev, Cd002207 Mattick, 2004, Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Database Syst Rev, 3, CD002207 Gowing, 2017, Buprenorphine for managing opioid withdrawal, Cochrane Database Syst Rev, 2, Cd002025 Manhapra, 2016, Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration, Drug Alcohol Depend, 160, 82, 10.1016/j.drugalcdep.2015.12.035 Saulle, 2017, Supervised dosing with a long-acting opioid medication in the management of opioid dependence, Cochrane Database Syst Rev, 4, Cd011983 2016 Dashe, 1998, Opioid detoxification in pregnancy, Obstet Gynecol, 92, 854 Stewart, 2013, The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy, Am J Obstet Gynecol, 209, 267.e1, 10.1016/j.ajog.2013.05.026 2017, Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy, Obstet Gynecol, 130, e81, 10.1097/AOG.0000000000002235 Jones, 2012, Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review, Addiction, 107, 5, 10.1111/j.1360-0443.2012.04035.x Tran, 2017, Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women, Pharmacotherapy, 37, 824, 10.1002/phar.1958 Sachs, 2013, The transfer of drugs and therapeutics into human breast milk: an update on selected topics, Pediatrics, 132, e796, 10.1542/peds.2013-1985 Kocherlakota, 2014, Neonatal abstinence syndrome, Pediatrics, 134, e547, 10.1542/peds.2013-3524 Kaltenbach, 2018, Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes, Drug Alcohol Depend, 185, 40, 10.1016/j.drugalcdep.2017.11.030 DuPont, 2018, The opioid epidemic is an historic opportunity to improve both prevention and treatment, Brain Res Bull, 138, 112, 10.1016/j.brainresbull.2017.06.008 Goodman, 2009, Strengths and difficulties questionnaire as a dimensional measure of child mental health, J Am Acad Child Adolesc Psychiatry, 48, 400, 10.1097/CHI.0b013e3181985068 Minozzi, 2014, Maintenance treatments for opiate-dependent adolescents, Cochrane Database Syst Rev, Cd007210 Fishman, 2010, Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility, Addiction, 105, 1669, 10.1111/j.1360-0443.2010.03015.x Marsch, 2005, Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial, Arch Gen Psychiatry, 62, 1157, 10.1001/archpsyc.62.10.1157 Woody, 2008, Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial, JAMA, 300, 2003, 10.1001/jama.2008.574 Matson, 2014, A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic, J Addict Med, 8, 176 Harrison, 2018, Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone, or naltrexone maintenance therapy, Anesthesiol Clin, 36, 345, 10.1016/j.anclin.2018.04.002 Neumann, 2013, A preliminary study comparing methadone and buprenorphine in patients with chronic pain and co-existent opioid addiction, J Addict Dis, 32, 68, 10.1080/10550887.2012.759872